JPS6327023B2 - - Google Patents
Info
- Publication number
- JPS6327023B2 JPS6327023B2 JP55050735A JP5073580A JPS6327023B2 JP S6327023 B2 JPS6327023 B2 JP S6327023B2 JP 55050735 A JP55050735 A JP 55050735A JP 5073580 A JP5073580 A JP 5073580A JP S6327023 B2 JPS6327023 B2 JP S6327023B2
- Authority
- JP
- Japan
- Prior art keywords
- membrane module
- plasma
- blood
- molecular weight
- pressure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000012528 membrane Substances 0.000 claims description 92
- 210000004369 blood Anatomy 0.000 claims description 29
- 239000008280 blood Substances 0.000 claims description 29
- 239000000126 substance Substances 0.000 claims description 26
- 210000000601 blood cell Anatomy 0.000 claims description 19
- 238000009795 derivation Methods 0.000 claims description 8
- 230000004087 circulation Effects 0.000 claims description 2
- 238000001514 detection method Methods 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 210000002381 plasma Anatomy 0.000 description 43
- 239000000306 component Substances 0.000 description 24
- 238000000926 separation method Methods 0.000 description 9
- 239000012530 fluid Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000012510 hollow fiber Substances 0.000 description 5
- 108010088751 Albumins Proteins 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 4
- 229920000219 Ethylene vinyl alcohol Polymers 0.000 description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 239000004715 ethylene vinyl alcohol Substances 0.000 description 4
- 108010074605 gamma-Globulins Proteins 0.000 description 4
- RZXDTJIXPSCHCI-UHFFFAOYSA-N hexa-1,5-diene-2,5-diol Chemical compound OC(=C)CCC(O)=C RZXDTJIXPSCHCI-UHFFFAOYSA-N 0.000 description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 206010018910 Haemolysis Diseases 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000008588 hemolysis Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 108010044091 Globulins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002637 fluid replacement therapy Methods 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
Landscapes
- External Artificial Organs (AREA)
Description
【発明の詳細な説明】
本発明は２種類の膜モジユールを用いて二重
過型血漿分離交換を安全、かつ安定して行うため
の装置に関するものである。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a device for safely and stably performing double-pass plasma separation exchange using two types of membrane modules.
腎不全、肝不全、自己免疫疾患等の治療法とし
て近時血漿分離交換法が知られている。この方法
は一般に血液透析と同じような手法により、血液
体外循環回路中で血漿を連続的に分離し、血球成
分を体外に返還する方法であるが、この場合廃棄
される血漿中には高分子量の毒素等と結合した状
態で低分子有効成分が含まれており、これをも除
去すると、それだけ多くの補液が必要となる。こ
のため従来からこうした高分子量物質を効率的に
除去しようとする試みが種々行なわれている。中
でも二重過型血漿分離交換法が注目を集めてい
る〔例えば医器学、Vol49、Supple（1979）259〜
261〕。この方法は分画分子量の異なる２種類の膜
モジユールを用い、第１膜モジユールで血漿成分
と血球成分とに分離した後、この血漿成分を第２
の膜モジユールで高分子量物質と低分子量物質と
に分離して、高分子量物質だけを選択的に除去
し、低分子量物質を血球成分とともに体内に返還
する方法である。 Plasma separation and exchange methods have recently been known as a treatment for renal failure, liver failure, autoimmune diseases, and the like. This method generally uses a method similar to hemodialysis to continuously separate plasma in an extracorporeal blood circulation circuit and return blood cell components outside the body, but in this case, the discarded plasma contains high molecular weight It contains low-molecular active ingredients bound to toxins, etc., and if these are also removed, more fluid replacement will be required. For this reason, various attempts have been made to efficiently remove such high molecular weight substances. Among them, the double-layer plasma separation method is attracting attention [for example, Igakugaku, Vol. 49, Supple (1979) 259~
261]. This method uses two types of membrane modules with different molecular weight cutoffs, and after the first membrane module separates plasma components and blood cell components, this plasma component is separated into the second membrane module.
This method separates high-molecular weight substances and low-molecular weight substances using a membrane module, selectively removes only the high-molecular weight substances, and returns the low-molecular weight substances to the body together with blood cell components.
本発明はこのような方法をシステム化するにあ
たつて、血液体外循環回路内の圧力や流量を自動
的にコントロールして、安全に、かつ安定に二重
過型血漿分離交換を行なうことのできる装置を
提供しようとするものである。 In systematizing such a method, the present invention aims to automatically control the pressure and flow rate in the blood extracorporeal circulation circuit to safely and stably perform double-layer plasma separation exchange. The aim is to provide a device that can.
すなわち、本発明は血液体外循環回路中に第１
の膜モジユールと第２の膜モジユールを設け、体
内から導出された血液を第１の膜モジユールで血
球成分と血漿成分とに分離し、この血漿成分をさ
らに第２の膜モジユールで高分子量物質と低分子
量物質とに分離するとともに、上記血球成分と低
分子量物質を合流させた後、体内に返還する血液
処理装置において、上記第１の膜モジユールから
第２の膜モジユールに至る血漿導出回路に血漿導
出圧力を検出する圧力検出計とポンプをこの順序
で設け、かつ上記第１の膜モジユールの血球成分
導出回路に圧力検出計との連動制御により第１の
膜モジユールの血液側の圧力を調整するバルブを
設け、しかも上記第２の膜モジユールの高分子量
物質排出回路に、ポンプとの連動制御により、第
２の膜モジユールの血漿導入量と高分子量物質排
出量の流量比が所定値となるように流量調整可能
なポンプを設けたことを特徴とする血液処理装置
である。 That is, the present invention provides a first
A membrane module and a second membrane module are provided, and the blood drawn from the body is separated into blood cell components and plasma components by the first membrane module, and this plasma component is further separated into high molecular weight substances by the second membrane module. In a blood processing device that separates the blood cell components and low molecular weight substances and returns them to the body after combining the blood cell components and the low molecular weight substances, the plasma is transferred to the plasma derivation circuit from the first membrane module to the second membrane module. A pressure detector and a pump for detecting the derivation pressure are provided in this order, and the pressure on the blood side of the first membrane module is adjusted by interlocking control with the pressure detector in the blood cell component deriving circuit of the first membrane module. A valve is provided in the high molecular weight substance discharge circuit of the second membrane module, and the flow rate ratio between the amount of plasma introduced into the second membrane module and the amount of high molecular weight substance discharged from the second membrane module becomes a predetermined value by interlocking control with a pump. This blood processing device is characterized in that it is equipped with a pump that can adjust the flow rate.
本発明において第１の膜モジユールに用いる膜
は、血球成分と血漿成分を分離するものであるか
ら、通常0.02〜0.4μ、好ましくは0.1μ程度の平均
有効微孔径の微孔構造をもつ膜、例えばポリビニ
ルアルコール（PVA）系、エチレン−ビニルア
ルコール（EVA）系共重合体、セルロースアセ
テート等のセルロース誘導体、ポリオレフイン、
ポリアクリロニトリル、ポリアミド、ポリエステ
ル、ポリスルホン等からなる均質微孔膜や非対称
構造膜が用いられる。 In the present invention, the membrane used in the first membrane module is for separating blood cell components and plasma components, and therefore a membrane having a microporous structure with an average effective pore diameter of usually 0.02 to 0.4μ, preferably about 0.1μ; For example, polyvinyl alcohol (PVA), ethylene-vinyl alcohol (EVA) copolymers, cellulose derivatives such as cellulose acetate, polyolefins,
Homogeneous microporous membranes or asymmetrically structured membranes made of polyacrylonitrile, polyamide, polyester, polysulfone, etc. are used.
第２の膜モジユールに用いる膜は、血漿成分を
選択的に高分子量物質と低分子量物質に分離する
ものであり、その目的によつて特定の分画分子量
を有する膜が使用できる。例えば本発明装置を自
己免疫性疾患の治療に用いる場合には、分画分子
量が10万の膜を使用する。これは自己免疫性疾患
の病因物質が分子量が約16万であるγ−グロブリ
ンと結合した形で存在することが多いので、分子
量がこれより大きい物質を除去し、それより低分
子量で、かつ生体にとつて有用な分子量67000の
アルブミン等を還流しなければならない。従つて
分画分子量が10万の膜を用いるとγ−グロブリン
とアルブミンをシヤープに分画することができ
る。 The membrane used in the second membrane module selectively separates plasma components into high molecular weight substances and low molecular weight substances, and a membrane having a specific molecular weight cutoff can be used depending on the purpose. For example, when the device of the present invention is used to treat autoimmune diseases, a membrane with a molecular weight cutoff of 100,000 is used. This is because the pathogenic substances of autoimmune diseases often exist in a form bound to γ-globulin, which has a molecular weight of about 160,000, so substances with a larger molecular weight are removed, and substances with a lower molecular weight and biological bodies are removed. Albumin, which has a molecular weight of 67,000 and is useful for reflux, must be refluxed. Therefore, by using a membrane with a molecular weight cutoff of 100,000, it is possible to sharply fractionate γ-globulin and albumin.
第２の膜としては、血漿成分を加圧下に分画分
離できるものならばいかなるものでもよく、その
意味で限外過能をもつ膜が広く使用できる。 As the second membrane, any membrane may be used as long as it can fractionate and separate plasma components under pressure, and in this sense, membranes having ultrasuperpower can be widely used.
上述した性能の膜は平膜は中空糸膜の形状で用
い膜モジユールを構成する。通常モジユールの製
作の容易さや小型化の点から中空糸膜が用いられ
る。 Membranes with the above-mentioned performance are used in the form of flat membranes or hollow fiber membranes to constitute a membrane module. Generally, hollow fiber membranes are used from the viewpoint of ease of manufacturing modules and miniaturization.
次に本発明装置の一実施例を第１図に示す系統
図にて説明する。 Next, one embodiment of the apparatus of the present invention will be explained with reference to the system diagram shown in FIG.
まず患者から血液導入口１を通してポンプM1
により血液導入回路３に血液を導入し、一旦血液
貯留器１５に貯留する。該血液貯留器１５には圧
力計P1が設けられており、第１の膜モジユール
１１での目詰りその他の要因により異常高圧とな
るのをモニターしている。 First, pump M 1 from the patient through blood inlet 1.
Blood is introduced into the blood introduction circuit 3 and temporarily stored in the blood reservoir 15. The blood reservoir 15 is provided with a pressure gauge P1 to monitor abnormally high pressure caused by clogging in the first membrane module 11 or other factors.
この第１の膜モジユール１１はポリビニルアル
コール系中空糸膜等の過膜１２によつて仕切ら
れており、血液貯留器１５から導入された血液
は、血液導入側のポンプM1の陽圧と、血漿導出
回路４に設けられたポンプM2による陰圧により、
過膜１２を介して血球成分と血漿成分とに分離
される。ここでポンプM2の流量は所望の値にセ
ツトされ、常時一定量の血漿を分離するようにし
ている。第１の膜モジユールで分離された血漿成
分は血漿導出回路４に設けられた血漿貯留器１６
を通つて第２の膜モジユール１３に送られること
になるが、過膜１２の目詰りにもかかわらず血
漿流量を一定に維持するためには膜間圧力差を大
きくする必要がある。この場合血漿の導出圧力に
より所定の膜間圧力差を得ようとすると異常な陰
圧を生じて溶血等を起す危険性がある。 This first membrane module 11 is partitioned by a membrane 12 such as a polyvinyl alcohol hollow fiber membrane, and the blood introduced from the blood reservoir 15 is connected to the positive pressure of the pump M1 on the blood introduction side. Due to the negative pressure caused by the pump M 2 provided in the plasma extraction circuit 4,
The blood cells are separated into blood cell components and plasma components via the membrane 12. Here, the flow rate of pump M2 is set to a desired value so that a constant amount of plasma is separated at all times. The plasma components separated by the first membrane module are transferred to a plasma reservoir 16 provided in the plasma derivation circuit 4.
However, in order to maintain a constant plasma flow rate despite clogging of the membrane 12, it is necessary to increase the transmembrane pressure difference. In this case, if an attempt is made to obtain a predetermined transmembrane pressure difference by the plasma discharge pressure, there is a risk that abnormal negative pressure will occur and hemolysis or the like will occur.
そこで本発明では、この第１の膜モジユール１
１から第２の膜モジユール１３に至る血漿導出回
路４に設けられた血漿貯留器１６に圧力計P2を
設け、第１の膜モジユール１１から導出される血
漿の圧力を感知するとともに、この圧力計P2と
第１の膜モジユール１１で分離された血球成分の
導出回路７に設けたバルブＶとの連動制御によ
り、バルブＶを絞つて、第１の膜モジユール１の
血液側の圧力を調整し、膜に異常な陰圧が加わる
ことを防止している。またポンプM2は一定流量
となるように設定しているため、膜が目詰りする
と、所定の血漿導出量を得るためには膜間圧力差
を大きくしなければならない。そのため血液側の
供給圧力が一定な場合には血漿導出圧力を小さく
しなければ所定の血漿導出量を得ることができな
い。しかし、血漿導出圧力が異常な陰圧、例えば
−40mmHg以下になると血球成分に損傷を与える
危険が大きくなる。本発明では血漿導出圧力を検
出する圧力検出器P2が設定圧以下となるバルブ
Ｖを絞つて血液側の圧力を大きくして、所定の膜
間圧力差を得るようにしている。 Therefore, in the present invention, this first membrane module 1
A pressure gauge P2 is provided in the plasma reservoir 16 provided in the plasma derivation circuit 4 extending from the first membrane module 1 to the second membrane module 13 to sense the pressure of the plasma derived from the first membrane module 11, and to detect the pressure of the plasma derived from the first membrane module 11. Through interlocking control between the meter P 2 and the valve V provided in the derivation circuit 7 for blood cell components separated by the first membrane module 11, the valve V is throttled to adjust the pressure on the blood side of the first membrane module 1. This prevents abnormal negative pressure from being applied to the membrane. Furthermore, since the pump M 2 is set to have a constant flow rate, if the membrane becomes clogged, the transmembrane pressure difference must be increased in order to obtain a predetermined amount of plasma discharged. Therefore, when the supply pressure on the blood side is constant, the predetermined amount of plasma to be delivered cannot be obtained unless the plasma delivery pressure is reduced. However, if the plasma outlet pressure becomes abnormally negative, for example -40 mmHg or less, there is a greater risk of damaging blood cell components. In the present invention, when the pressure detector P2 detecting the blood plasma delivery pressure becomes lower than the set pressure, the valve V is throttled to increase the pressure on the blood side to obtain a predetermined transmembrane pressure difference.
一方、第２の膜モジユール１３は内部がEVA
膜等の過膜１４で仕切られており、該第２の膜
モジユール１３に導入された血漿はポンプM2と
排出回路５に設けられたポンプM3との流量差に
よつて生ずる陽圧により、高分子量物質と低分子
量物質とに分離される。分離された高分子量物質
は排出回路５を通つて導出され、貯留器１９をへ
て貯留容器１０に排出されるが、この場合ポンプ
M2とM3の流量がアンバランスになると第２の膜
モジユール１３に異常な圧力が加わり、安定した
過・分離作用が得られない。 On the other hand, the inside of the second membrane module 13 is made of EVA.
It is partitioned by a membrane 14 such as a membrane, and the plasma introduced into the second membrane module 13 is separated by a positive pressure generated by the flow rate difference between the pump M 2 and the pump M 3 provided in the discharge circuit 5. , separated into high molecular weight substances and low molecular weight substances. The separated high molecular weight substance is led out through the discharge circuit 5, passes through the reservoir 19, and is discharged into the reservoir 10, but in this case, the pump
If the flow rates of M 2 and M 3 become unbalanced, abnormal pressure will be applied to the second membrane module 13, making it impossible to obtain a stable over-separation effect.
そこで本発明ではポンプM2とM3の流量比を連
動制御して第２の膜モジユール１３における血漿
導入量と高分子量物質排出量の流量比を所定値に
調整しているものである。例えばポンプM2の流
量が15〜20mm／分であつた場合、ポンプM3の流
量はその1/3〜1/4、すなわち３〜５mm／分となる
ように自動的に制御されることになる。なお、図
中P3は貯留器１９に設けられた圧力計であり、
第２の膜モジユール１３に高圧が加わると過膜
１４がパンクする危険性があるため、この圧力計
P3でモニターしている。 Therefore, in the present invention, the flow rate ratio of the pumps M 2 and M 3 is controlled in conjunction with each other to adjust the flow rate ratio between the amount of plasma introduced into the second membrane module 13 and the amount of high molecular weight substance discharged to a predetermined value. For example, if the flow rate of pump M 2 is 15 to 20 mm/min, the flow rate of pump M 3 will be automatically controlled to 1/3 to 1/4 of that, or 3 to 5 mm/min. Become. In addition, P3 in the figure is a pressure gauge provided in the reservoir 19,
If high pressure is applied to the second membrane module 13, there is a risk that the membrane 14 will be punctured.
Monitored with P3 .
他方、第２の膜モジユール１３で分離された低
分子量物質は回路６を通つて血液貯留器１８に送
られ、第１の膜モジユール１１から導出回路７を
通つて送られる血球成分と合流した後、血液導出
口２から患者の体内に返還されることになる。 On the other hand, the low molecular weight substances separated in the second membrane module 13 are sent to the blood reservoir 18 through the circuit 6, and after combining with the blood cell components sent from the first membrane module 11 through the derivation circuit 7. , the blood is returned to the patient's body through the blood outlet 2.
また、第２の膜モジユール１３において除去さ
れた血漿分を補うため、補液容器９からアルブミ
ンやHES等の補液を導入回路８を通して血液貯
留器１８に送ることが望ましい。この補液を導入
するに際し、導入回路８に設けられた補液導入用
のポンプM4と高分子量物質の排出回路５に設け
られたポンプM3との連動制御により高分子量物
質の導出量と補液の注入量とが等量となるように
流量調整している。例えば前記したごとくポンプ
M3の流量が３〜５mm／分の場合、ポンプM4もこ
れと同じ流量となるよう調整されるものであり、
これにより補液は過不足なく血液貯留器１８に注
入されることになる。なお、P1′は血球成分導出
回路７の血球貯留器１７に設けられた圧力計であ
り、血球成分導出回路７に異常な圧力が加わるの
をモニターしている。 Furthermore, in order to supplement the plasma removed in the second membrane module 13, it is desirable to send a replacement fluid such as albumin or HES from the replacement fluid container 9 to the blood reservoir 18 through the introduction circuit 8. When introducing this replacement fluid, the amount of high molecular weight substances to be drawn out and the amount of replacement fluid are controlled by interlocking control of the pump M 4 for introducing replacement fluid provided in the introduction circuit 8 and the pump M 3 provided in the discharge circuit 5 for high molecular weight substances. The flow rate is adjusted so that the injection amount is equal to the injection amount. For example, as mentioned above, the pump
If the flow rate of M3 is 3 to 5 mm/min, pump M4 is adjusted to have the same flow rate.
As a result, the replacement fluid is injected into the blood reservoir 18 in just the right amount. Note that P 1 ' is a pressure gauge provided in the blood cell reservoir 17 of the blood cell component deriving circuit 7, and monitors whether abnormal pressure is applied to the blood cell component deriving circuit 7.
このように本発明によれば、二重過型血漿分
離を行なうにあたり、第１の膜モジユールと第２
の膜モジユールを備えた血液体外循環回路におい
て、血液成分や過膜の圧力が常に所定値となる
ように制御されるため、きわめて安全で安定した
治療が可能となり、システム全体をコンパクト化
できる。 As described above, according to the present invention, when performing double-layer plasma separation, the first membrane module and the second membrane module are separated.
In an extracorporeal blood circulation circuit equipped with a membrane module, the blood components and membrane pressure are always controlled to a predetermined value, making extremely safe and stable treatment possible and making the entire system more compact.
実施例
平均孔径0.04μ、内径400μ、膜厚200μをもつ均
質微孔構造のポリビニルアルコール系中空糸膜
を、0.15m2の膜面積をもつように円筒型カートリ
ツジに組み込み、第１の膜モジユールとした。さ
らに多孔質支持層と微孔構造層からなる非対称構
造（特開昭55−35969号参照）をもつEVA系中空
糸膜（平均微孔孔径110Å、内径330μ、膜厚45μ）
を、0.9m2の膜面積となるように同様な円筒状カ
ートリツジに組み込み、第２の膜モジユールとし
た。これらの膜モジユールを第１図に示す回路に
セツトしてリユウマチ性関節炎患者の血液処理を
行なつた。第１の膜モジユールでの血漿分離はポ
ンプM1で血流量を120ml／minに調整し、さらに
ポンプM2の送液量を22ml／minに調整した上で、
圧力計P2が０〜−20mmHgの範囲となるようにバ
ルブＶが運転される制御回路を設けた。その際の
圧力計P1の指示値は80mmHgであつた。この血漿
分離操作での溶血は遊離ヘモグロビンで１mg／dl
であり、実質的に溶血は殆んど生じない良好な血
漿分離であつた。Example A polyvinyl alcohol hollow fiber membrane with a homogeneous microporous structure having an average pore diameter of 0.04μ, an inner diameter of 400μ, and a membrane thickness of 200μ was assembled into a cylindrical cartridge so as to have a membrane area of 0.15m 2 , and was used as the first membrane module. did. Furthermore, an EVA-based hollow fiber membrane (average micropore diameter 110 Å, inner diameter 330 μ, membrane thickness 45 μ) has an asymmetric structure (see JP-A-55-35969) consisting of a porous support layer and a microporous structure layer.
was assembled into a similar cylindrical cartridge so as to have a membrane area of 0.9 m 2 to form a second membrane module. These membrane modules were set in the circuit shown in FIG. 1 to treat blood of patients with rheumatoid arthritis. Plasma separation in the first membrane module is performed by adjusting the blood flow rate to 120 ml/min with pump M 1 , and adjusting the flow rate of pump M 2 to 22 ml/min.
A control circuit was provided in which the valve V was operated so that the pressure gauge P2 was in the range of 0 to -20 mmHg. At that time, the reading on the pressure gauge P1 was 80 mmHg. Hemolysis during this plasma separation procedure was 1 mg/dl of free hemoglobin.
This was a good plasma separation with virtually no hemolysis.
さらにポンプM2で導出された血漿は第２の膜
モジユールで高分子量物質を別した後、第１の
膜モジユールで分離された血球成分と混合し患者
の体内に還流した。この第２の膜による過にお
いて、血漿中のγ−グロブリンの除去はポンプ
M3からの系外への排液中のアルブミンとγ−グ
ロブリン両蛋白の組成比（Ａ／Ｇ）が分析の結果
0.4になつており、これは過前の血漿中のＡ／
Ｇが0.6であつたことと比較して、明らかにγ−
グロブリンの血液中からの除去が行われたことを
示している。 Further, the plasma drawn out by the pump M 2 was separated from high molecular weight substances by the second membrane module, mixed with blood cell components separated by the first membrane module, and returned into the patient's body. In this second membrane, the removal of γ-globulin from the plasma is carried out by the pump.
The composition ratio (A/G) of both albumin and γ-globulin in the drainage fluid from M3 to the outside of the system was analyzed.
0.4, which is the previous plasma A/
Compared to the fact that G was 0.6, it is clear that γ-
This indicates that globulin has been removed from the blood.
第１図は本発明による血液処理装置の一例を示
す系統図である。
１１……第１の膜モジユール、１３……第２の
膜モジユール、M1，M2，M3，M4……ポンプ、
P1，P′1，P2，P3……圧力検出計。
FIG. 1 is a system diagram showing an example of a blood processing apparatus according to the present invention. DESCRIPTION OF SYMBOLS 11...First membrane module, 13...Second membrane module, M1 , M2 , M3 , M4 ...Pump,
P 1 , P′ 1 , P 2 , P 3 ...Pressure detection gauge.
Claims (1)
１と第２の膜モジユール１３を設け、体内から導
出された血液を第１の膜モジユール１１で血球成
分と血漿成分とに分離し、この血漿成分をさらに
第２の膜モジユール１３で高分子量物質と低分子
量物質とに分離するとともに、上記血球成分と低
分子量物質を合流させた後、体内に返還する血液
処理装置において、上記第１の膜モジユール１１
から第２の膜モジユール１３に至る血漿導出回路
４に血漿導出圧力を検出する圧力検出計P2とポ
ンプM2をこの順序で設け、かつ上記第１の膜モ
ジユール１１の血球成分導出回路７に圧力検出計
P2との連動制御により第１の膜モジユール１１
の血液側の圧力を調整するバルブＶを設け、しか
も上記第２の膜モジユール１３の高分子量物質排
出回路５に、ポンプM2連動制御により第２の膜
モジユール１３の血漿導入量と高分子量物質排出
量の流量比が所定値となるように流量調整可能な
ポンプM3を設けたことを特徴とする血液処理装
置。1. A first membrane module 1 in the blood extracorporeal circulation circuit.
1 and a second membrane module 13 are provided, blood drawn from the body is separated into blood cell components and plasma components by the first membrane module 11, and this plasma component is further separated into high molecular weight substances by the second membrane module 13. In the blood processing device, the first membrane module 11
A pressure detector P 2 for detecting plasma extraction pressure and a pump M 2 are provided in this order in the plasma derivation circuit 4 extending from the second membrane module 13 to the second membrane module 13, and in the blood cell component derivation circuit 7 of the first membrane module 11. pressure detection meter
The first membrane module 11 is controlled in conjunction with P 2.
A valve V is provided to adjust the pressure on the blood side of the second membrane module 13, and a pump M2 is connected to the high molecular weight substance discharge circuit 5 of the second membrane module 13 to control the amount of plasma introduced into the second membrane module 13 and the high molecular weight substance. A blood processing device comprising a pump M3 capable of adjusting the flow rate so that the flow rate ratio of the discharge amount becomes a predetermined value.
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP5073580A JPS56145859A (en) | 1980-04-16 | 1980-04-16 | Treating device for blood |
| US06/252,245 US4350594A (en) | 1980-04-16 | 1981-04-08 | Blood purification using plural ultrafiltration stages |
| DE8181301613T DE3171458D1 (en) | 1980-04-16 | 1981-04-13 | Blood treatment apparatus |
| EP81301613A EP0038203B1 (en) | 1980-04-16 | 1981-04-13 | Blood treatment apparatus |
| CA000375402A CA1151044A (en) | 1980-04-16 | 1981-04-14 | Blood treatment apparatus and method of treating blood |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP5073580A JPS56145859A (en) | 1980-04-16 | 1980-04-16 | Treating device for blood |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS56145859A JPS56145859A (en) | 1981-11-12 |
| JPS6327023B2 true JPS6327023B2 (en) | 1988-06-01 |
Family
ID=12867097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP5073580A Granted JPS56145859A (en) | 1980-04-16 | 1980-04-16 | Treating device for blood |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS56145859A (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5878668A (en) * | 1981-11-04 | 1983-05-12 | 株式会社クラレ | Blood treating apparatus |
| JPS58206758A (en) * | 1982-05-28 | 1983-12-02 | 株式会社クラレ | Blood serum separation apparatus |
| JPS6173669A (en) * | 1984-09-20 | 1986-04-15 | 旭メデイカル株式会社 | Serum purification apparatus |
| US4708713A (en) * | 1984-11-16 | 1987-11-24 | Anisa Medical, Inc. | Method and system for removing immunosuppressive components from the blood of mammals |
-
1980
- 1980-04-16 JP JP5073580A patent/JPS56145859A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS56145859A (en) | 1981-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0038203B1 (en) | Blood treatment apparatus | |
| US4397747A (en) | Apparatus for plasma separation/exchange by double filtration | |
| US4747952A (en) | Method and apparatus for plasma treatment | |
| US4839055A (en) | Method for treating blood and apparatus therefor | |
| JPH08295630A (en) | Plasma separation | |
| US20030032914A1 (en) | Blood processing system | |
| JPS6327023B2 (en) | ||
| US4832839A (en) | Hemopurification apparatus | |
| JPS6327024B2 (en) | ||
| US7632474B2 (en) | Device, cartridge and method for solving powder in liquid, when manufacturing a dialysis fluid | |
| JPH019575Y2 (en) | ||
| JPS6040303B2 (en) | Double filtration plasma exchanger | |
| JPS60256465A (en) | Blood treating apparatus | |
| JPH059008Y2 (en) | ||
| JPH01104272A (en) | Blood treatment apparatus | |
| JPS6040302B2 (en) | Double filtration plasma exchanger | |
| Sanz‐Moreno et al. | Hemodiafiltration in two chambers without replacement fluid: a clinical study | |
| JPH0244759Y2 (en) | ||
| JPS64940Y2 (en) | ||
| JPS60179065A (en) | Blood treating apparatus | |
| Nosé et al. | Plasma filtration detoxification on hepatic patients: its optimal operating conditions | |
| JPH043985B2 (en) | ||
| JPS6099263A (en) | Blood treating apparatus | |
| JPS609821B2 (en) | blood purification device | |
| JPH0448066B2 (en) |